|Bid||1.6800 x 0|
|Ask||1.6950 x 0|
|Day's range||1.6650 - 1.7150|
|52-week range||0.9650 - 3.0400|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.28|
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.
Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...